Is JANX or FULC more profitable?

Janux Therapeutics' return on equity of -12.93% beat Fulcrum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -12.93% -12.23% Fulcrum Therapeutics N/A -27.80% -26.32%

Does the media prefer JANX or FULC?

In the previous week, Janux Therapeutics and Janux Therapeutics both had 2 articles in the media. Janux Therapeutics' average media sentiment score of 1.81 beat Fulcrum Therapeutics' score of 1.45 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LBRX or FULC more profitable?

LB Pharmaceuticals' return on equity of 0.00% beat Fulcrum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A N/A N/A Fulcrum Therapeutics N/A -27.80% -26.32%

Does the media prefer LBRX or FULC?

In the previous week, LB Pharmaceuticals had 5 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 7 mentions for LB Pharmaceuticals and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.45 beat LB Pharmaceuticals' score of 0.84 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is REPL or FULC more profitable?

Fulcrum Therapeutics' return on equity of -27.80% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -128.57% -82.35% Fulcrum Therapeutics N/A -27.80% -26.32%

Does the media refer more to REPL or FULC?

In the previous week, Replimune Group had 3 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 5 mentions for Replimune Group and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.45 beat Replimune Group's score of 0.88 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, IVA or FULC?

Fulcrum Therapeutics has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 176.16 -$400.67M N/A N/A Fulcrum Therapeutics $80M 2.95 -$74.88M -$1.15 N/A

Is IVA or FULC more profitable?

Inventiva's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Fulcrum Therapeutics N/A -27.80% -26.32%

Does the media prefer IVA or FULC?

In the previous week, Inventiva had 1 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 3 mentions for Inventiva and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.45 beat Inventiva's score of 0.62 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, GLAS or FULC?

Glass House Brands has higher revenue and earnings than Fulcrum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands $176.02M 5.22 N/A N/A N/A Fulcrum Therapeutics $80M 2.95 -$74.88M -$1.15 N/A

Is GLAS or FULC more profitable?

Glass House Brands' return on equity of 0.00% beat Fulcrum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Glass House Brands N/A N/A N/A Fulcrum Therapeutics N/A -27.80% -26.32%

Does the media prefer GLAS or FULC?

In the previous week, Glass House Brands had 1 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 3 mentions for Glass House Brands and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.45 beat Glass House Brands' score of -0.18 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glass House Brands 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Fulcrum Therapeutics (FULC) Competitors

$3.54 +0.04 (+1.14%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$3.50 -0.04 (-0.99%)

As of 07:22 AM Eastern

Compare

FULC vs. JANX, LBRX, REPL, IVA, and GLAS

Should you buy Fulcrum Therapeutics stock or one of its competitors? MarketBeat compares Fulcrum Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fulcrum Therapeutics include Janux Therapeutics (JANX), LB Pharmaceuticals (LBRX), Replimune Group (REPL), Inventiva (IVA), and Glass House Brands (GLAS). These companies are all part of the "pharmaceutical products" industry.

How does Fulcrum Therapeutics compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

In the previous week, Janux Therapeutics and Janux Therapeutics both had 2 articles in the media. Janux Therapeutics' average media sentiment score of 1.81 beat Fulcrum Therapeutics' score of 1.45 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Janux Therapeutics has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 3.01, indicating that its stock price is 201% more volatile than the broader market.

Fulcrum Therapeutics has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	98.42	-$113.62M	-$1.84	N/A
Fulcrum Therapeutics	$80M	2.95	-$74.88M	-$1.15	N/A

Janux Therapeutics' return on equity of -12.93% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-12.93%	-12.23%
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Janux Therapeutics presently has a consensus target price of $38.08, indicating a potential upside of 135.96%. Fulcrum Therapeutics has a consensus target price of $8.20, indicating a potential upside of 131.64%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Janux Therapeutics is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Janux Therapeutics beats Fulcrum Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, LB Pharmaceuticals had 5 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 7 mentions for LB Pharmaceuticals and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.45 beat LB Pharmaceuticals' score of 0.84 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

LB Pharmaceuticals' return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	N/A	N/A
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

LB Pharmaceuticals presently has a consensus price target of $39.50, indicating a potential upside of 22.48%. Fulcrum Therapeutics has a consensus price target of $8.20, indicating a potential upside of 131.64%. Given Fulcrum Therapeutics' higher possible upside, analysts plainly believe Fulcrum Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

LB Pharmaceuticals has higher earnings, but lower revenue than Fulcrum Therapeutics. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Fulcrum Therapeutics	$80M	2.95	-$74.88M	-$1.15	N/A

Summary

LB Pharmaceuticals and Fulcrum Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Replimune Group has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 3.01, suggesting that its share price is 201% more volatile than the broader market.

Fulcrum Therapeutics' return on equity of -27.80% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-128.57%	-82.35%
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Fulcrum Therapeutics has higher revenue and earnings than Replimune Group. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A
Fulcrum Therapeutics	$80M	2.95	-$74.88M	-$1.15	N/A

Replimune Group currently has a consensus target price of $8.13, indicating a potential downside of 18.26%. Fulcrum Therapeutics has a consensus target price of $8.20, indicating a potential upside of 131.64%. Given Fulcrum Therapeutics' higher probable upside, analysts clearly believe Fulcrum Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Replimune Group had 3 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 5 mentions for Replimune Group and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.45 beat Replimune Group's score of 0.88 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Fulcrum Therapeutics beats Replimune Group on 9 of the 14 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Inventiva?

Inventiva (NASDAQ:IVA) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Inventiva currently has a consensus price target of $16.56, indicating a potential upside of 285.01%. Fulcrum Therapeutics has a consensus price target of $8.20, indicating a potential upside of 131.64%. Given Inventiva's stronger consensus rating and higher possible upside, research analysts plainly believe Inventiva is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Fulcrum Therapeutics has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	176.16	-$400.67M	N/A	N/A
Fulcrum Therapeutics	$80M	2.95	-$74.88M	-$1.15	N/A

In the previous week, Inventiva had 1 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 3 mentions for Inventiva and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.45 beat Inventiva's score of 0.62 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Inventiva's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

Inventiva has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 3.01, meaning that its share price is 201% more volatile than the broader market.

Summary

Inventiva beats Fulcrum Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Glass House Brands?

Glass House Brands (NYSE:GLAS) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

In the previous week, Glass House Brands had 1 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 3 mentions for Glass House Brands and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.45 beat Glass House Brands' score of -0.18 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glass House Brands	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glass House Brands currently has a consensus target price of $17.00, suggesting a potential upside of 48.46%. Fulcrum Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 131.64%. Given Fulcrum Therapeutics' higher probable upside, analysts clearly believe Fulcrum Therapeutics is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Glass House Brands' return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	N/A	N/A	N/A
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

Glass House Brands has higher revenue and earnings than Fulcrum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	$176.02M	5.22	N/A	N/A	N/A
Fulcrum Therapeutics	$80M	2.95	-$74.88M	-$1.15	N/A

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 7.3% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Glass House Brands beats Fulcrum Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Fulcrum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FULC vs. The Competition

Export

Metric	Fulcrum Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$233.22M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-3.08	20.85	27.12	24.26
Price / Sales	2.95	314.01	587.25	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	0.55	8.49	10.89	6.29
Net Income	-$74.88M	$23.83M	$3.58B	$330.66M
7 Day Performance	-6.10%	-3.56%	-2.11%	-1.35%
1 Month Performance	2.61%	6.31%	3.28%	-0.64%
1 Year Performance	-55.19%	48.30%	26.33%	19.08%

Fulcrum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FULC Fulcrum Therapeutics	3.5877 of 5 stars	$3.54 +1.1%	$8.20 +131.6%	-54.8%	$233.22M	$80M	N/A	100	News Coverage
JANX Janux Therapeutics	3.8356 of 5 stars	$16.15 +4.8%	$40.15 +148.6%	-35.8%	$984.89M	$13.73M	N/A	30
LBRX LB Pharmaceuticals	1.8973 of 5 stars	$34.29 +2.6%	$39.50 +15.2%	N/A	$983.44M	N/A	N/A	16
REPL Replimune Group	1.0406 of 5 stars	$11.51 +0.3%	$8.13 -29.4%	-9.4%	$966.15M	N/A	N/A	210	News Coverage Options Volume
IVA Inventiva	2.4175 of 5 stars	$4.56 +16.9%	$16.56 +263.1%	+28.4%	$947.16M	$5.07M	N/A	100	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FULC) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulcrum Therapeutics (FULC) Competitors

FULC vs. JANX, LBRX, REPL, IVA, and GLAS

How does Fulcrum Therapeutics compare to Janux Therapeutics?

Summary

How does Fulcrum Therapeutics compare to LB Pharmaceuticals?

Summary

How does Fulcrum Therapeutics compare to Replimune Group?

Summary

How does Fulcrum Therapeutics compare to Inventiva?

Summary

How does Fulcrum Therapeutics compare to Glass House Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC vs. The Competition

Fulcrum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulcrum Therapeutics (FULC) Competitors

FULC vs. JANX, LBRX, REPL, IVA, and GLAS

How does Fulcrum Therapeutics compare to Janux Therapeutics?

Does the media prefer JANX or FULC?

Which has more risk & volatility, JANX or FULC?

Which has preferable valuation and earnings, JANX or FULC?

Is JANX or FULC more profitable?

Do insiders and institutionals believe in JANX or FULC?

Do analysts prefer JANX or FULC?

Summary

How does Fulcrum Therapeutics compare to LB Pharmaceuticals?

Does the media prefer LBRX or FULC?

Do insiders & institutionals hold more shares of LBRX or FULC?

Is LBRX or FULC more profitable?

Do analysts prefer LBRX or FULC?

Which has preferable earnings & valuation, LBRX or FULC?

Summary

How does Fulcrum Therapeutics compare to Replimune Group?

Which has more volatility and risk, REPL or FULC?

Is REPL or FULC more profitable?

Do institutionals and insiders hold more shares of REPL or FULC?

Which has stronger valuation & earnings, REPL or FULC?

Do analysts rate REPL or FULC?

Does the media refer more to REPL or FULC?

Summary

How does Fulcrum Therapeutics compare to Inventiva?

Do analysts rate IVA or FULC?

Which has better earnings and valuation, IVA or FULC?

Does the media prefer IVA or FULC?

Do institutionals & insiders hold more shares of IVA or FULC?

Is IVA or FULC more profitable?

Which has more volatility & risk, IVA or FULC?

Summary

How does Fulcrum Therapeutics compare to Glass House Brands?

Does the media prefer GLAS or FULC?

Do analysts recommend GLAS or FULC?

Is GLAS or FULC more profitable?

Which has better earnings and valuation, GLAS or FULC?

Do insiders & institutionals have more ownership in GLAS or FULC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC vs. The Competition

Fulcrum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools